

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-95) DILPACIMAB
 PRONUNCIATION dil pak' i mab
 THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin, anti-(notch ligand DLL4/vascular endothelial growth factor) (synthetic human PR-1283233 heavy chain), disulfide with synthetic human PR-1283233 light chain, dimer
2. Immunoglobulin G1-kappa, anti-(*Homo sapiens* Delta-like protein 4 (Drosophila Delta homolog 4, Delta4)) and anti-(*Homo sapiens* Vascular endothelial growth factor A (Vascular permeability factor, VEGF-A, VPF)), dual variable domain humanized mouse monoclonal antibody, bispecific; dual variable γ 1 heavy chain (1-577) [humanized VH anti-Delta4 (*Homo sapiens* IGHV3-48*01 (90%) –(IGHD)-IGHJ4*01 (93%)) [8.8.11] (1-118) -IGHG1*03-(1-6)-peptide (119-124) humanized VH anti-VEGF-A (*Homo sapiens* IGHV3-30*02 (77%) –(IGHD)-IGHJ4*01 (93%)) [8.9.16] (125-247) -*Homo sapiens* IGHG1*03 {CH1[R⁹⁷>K(344)], CH2[L⁴>A(364), L⁵>A(365)]} (248-577)] (350-334')-disulfide with dual variable κ light chain (1'-334') [humanized V-KAPPA anti-Delta4 (*Homo sapiens* IGKV1D-13*01 (88%) –IGHJ2*01) [6.3.9] (1'-107') -IGKC*01-(1-13)-peptide (108'-120') humanized V-KAPPA anti-VEGF-A (*Homo sapiens* IGKV1-16*01 (88%) –IGHJ1*01) [6.3.9] (121'-227') -*Homo sapiens* IGKC*01 (228'-334')], dimer (356-356":359-359")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	NFPMWVRQA	PGKGLEWVAT	50
ISSSDGTTY	RDSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVYYCARGY	100
YNSPFAYWGQ	GTLVTVSSAS	TKGPEVQLVE	SGGGLVQPGG	SLRLSCAASG	150
YTFTNYGMNW	VRQAPGKGLE	WVGWINTYTG	EPTYAADFKR	RFTFSLDTSK	200
STAYLQMNLS	RAEDTAVYYC	AKYPHYYGSS	HWYFDVWQGG	TLVTVSSAST	250
KGPSVFPLAP	SSKSTSGGTA	ALGCLVKDYF	PEPVTVSWNS	GALTSGVHTF	300
PAVLQSSGLY	SLSSVTVVPS	SSLGTQTYIC	NVNHKPSNTK	VDKKEPKSC	350
DKTHTCPPCP	APEAAGPSV	FLFPPKPKDT	LMISRTPEVT	CVVVDVSHED	400
PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	RVVSVLTVLH	QDWLNGKEYK	450
CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	LPPSREEMTK	NQVSLTCLVK	500
GFYPSDIAVE	WESNGQPENN	YKTTTPVLDL	DGSFFFLYSKL	TVDKSRWQQG	550
NVFSCSVME	ALHNHYTQKS	LSLSPGK			577

Light chain

DIQMTQSPSS	LSASVGDVRT	ITCRASEDIY	SNLAWYQQKP	GKAPKLLIYD	50'
TNNLADGVPS	RFSGSGSGTD	FTLTISLQP	EDFATYICQQ	YNNYPPTFGQ	100'
GTKLEIKRTV	AAPSVFIFPP	DIQMTQSPSS	LSASVGDVRT	ITCSASQDIS	150'
NYLNWYQQK	GKAPKVLIIYF	TSSLHSGVPS	RFSGSGSGTD	FTLTISLQP	200'
EDFATYICQQ	YSTVPWTFGQ	GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	250'
SVVCLLNIFY	PREAKVQWKV	DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	300'
LSKADYEKHK	VYACEVTHQG	LSSPVTKSFN	RGEC		334'

Disulfide bridges location

22-96	22"-96"	23'-88'	23'''-88'''	143'-208'	143'''-208'''	146-220
146"-220"	254'-314'	254'''-314'''	274-330	274"-330"	334'-350'	334'''-350'''
356-356"	359-359"	391-451	391"-451"	497-555	497"-555"	

Glycosylation sites (N)

Asn-427 Asn-427"

MOLECULAR FORMULA $C_{8888}H_{13570}N_{2342}O_{2768}S_{58}$. (non-glycosylated)

MOLECULAR WEIGHT 199.4 kDa (non-glycosylated)

TRADEMARK None as yet

SPONSOR AbbVie

CODE DESIGNATIONS PR-1283233, ABT-165

CAS REGISTRY NUMBER 1791420-09-1

UNII F27LAH6D5O

WHO NUMBER 10863

gbk